Ozurdex Dexamethasone Intravitreal Implant

1. Indications and Usage
Dexamethasone intravitreal implant is indicated for the treatment of macular edema (ME) following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), diabetic macular edema (DME), and for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
2. Dosage and Administration
Recommended Dosage: The recommended dosage is one 0.7 mg implant administered intravitreally into the affected eye.
Administration: Dosing should be performed by ophthalmologists experienced in intravitreal injections. The implant should be delivered through the pars plana.
Re-treatment: For retinal vein occlusions, repeat treatment should be considered based on clinical evaluation. For DME, re-treatment is generally not recommended until at least 6 months have elapsed since the previous implant.
Precautions: Treatment of both eyes simultaneously is not recommended.
3. Mechanism of Action
Dexamethasone is a corticosteroid that inhibits multiple inflammatory cytokines. This reduces edema, fibrin deposition, capillary leakage, and inflammatory cell migration. The polymer matrix coating allows for controlled release of the drug over approximately 6 months, at which point it biodegrades into carbon dioxide and water.
4. Safety and Warnings
Intraocular Pressure Elevation: Elevation of intraocular pressure and secondary glaucoma are common adverse reactions and may require treatment.
Cataract Formation: Cataract formation or progression is very common in patients with intact lenses.
Infection Risk: Intravitreal injection carries a risk of endophthalmitis and retinal detachment.
Contraindications: Contraindicated in patients with active or suspected ocular infections, including most viral, fungal, or bacterial diseases of the eye.
5. Adverse Reactions and Clinical Research
Common Adverse Reactions: The most frequent adverse reactions include increased intraocular pressure, cataract, eye pain, vitreous floaters, conjunctival hemorrhage, and vitreous detachment.
Clinical Research: Clinical trials have demonstrated that the implant significantly improves visual acuity and reduces retinal thickness in patients with ME and uveitis compared to baseline.
6. Drug Interactions
Concurrent Ocular Therapies: No formal drug-drug interaction studies have been conducted. Caution is advised when used concurrently with other ocular therapies.
Systemic Therapies: No systemic drug interactions have been documented due to the localized nature of the intravitreal administration.
7. Pharmaceutical Information
Composition: The implant contains 0.7 mg of dexamethasone. It is composed of a dexamethasone core and a poly(lactic-co-glycolide) (PLGA) polymer matrix.
Appearance: The implant is a white to off-white rod-shaped device sealed in a composite aluminum foil pouch.
Storage: Store at controlled room temperature.